Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Options Coach’s Substack by Taylor Selden. In this ...

AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...

Regeneron presents an interesting investment case. Its valuation doesn't fully capture Dupixent's strength or its pipeline potential. Bears worry about Eylea's patent cliff, but this seems priced in.